CD40 and neoplasm: Tumor growth inhibition following ISF35 treatment was abrogated in CD8 T cell-depleted mice (Fig. 3a), myeloid cell-depleted mice (Fig. 3b), and CD40 knockout mice (Fig. 3c), indicating a requirement for CD8+ T cells, myeloid cells, and CD40 signaling in host cells.